You can buy or sell VNDA and other stocks, options, ETFs, and crypto commission-free!
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Read More Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
Washington, District of Columbia
52 Week High
52 Week Low
Yahoo FinanceMay 2
Is Vanda Pharmaceuticals Inc. (VNDA) A Good Stock To Buy?
Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings.
Seeking AlphaMay 1
Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q1 2019 Results - Earnings Call Transcript
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2019 Results Earnings Conference Call May 1, 2019 4:30 AM ET Company Participants Jim Kelly - Executive Vice President, Chief Financial Officer, Treasurer Mihael Polymeropoulos - President and Chief Executive Officer Conference Call Participants Chris Howerton - Jefferies Joel Beatty - Citi Derek Archila - Stifel Esther Rajavelu - Oppenheimer Operator Good day ladies and gentlemen and welcome to the Vanda Pharmaceuticals' first quarter 2019 earnings conf...
Expected Jul 31, After Hours